ArticleScience advances2023
A "best-in-class" systemic biomarker predictor of clinically relevant knee osteoarthritis structural and pain progression.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Associations between biomarkers and skeletal muscle function in individuals with osteoarthritis: a systematic review and meta-analysis.Arthritis research & therapy · 2024Pooled it
- 15-PGDH inhibition in osteoarthritis: PGEBone research · 2026Review
- Evaluating the utility of prognostic enrichment in clinical trials: Applications to clinical trial design in osteoarthritis.Osteoarthritis and cartilage · 2026Article
- Immunonutritional biomarkers in osteoarthritis: mechanistic insights and prognostic potential.Frontiers in immunology · 2026Review
- Artificial intelligence in the biomechanics of knee osteoarthritis: biomechanical phenotyping, risk stratification, diagnosis, treatment and clinical translation-a narrative review.Frontiers in bioengineering and biotechnology · 2026Review
- Enzymatic Drivers of Cartilage Breakdown: Insights From a Bovine Osteoarthritis Explant Model.Orthopaedic surgery · 2026Article
- Letter to the Editor: Multi-omic profiling reveals age-specific blood biomarkers and aging-driven B cell remodeling in osteoarthritis.International journal of surgery (London, England) · 2026Article
- Article
- Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study.Osteoarthritis and cartilage open · 2025Article
- Novel approaches to the stratified management of knee osteoarthritis.Nature reviews. Rheumatology · 2025Review
- Synovial fluid as a complex molecular pool contributing to knee osteoarthritis.Nature reviews. Rheumatology · 2025Review
- Glenohumeral Osteoarthritis: Disease Burden, Current Understanding, and Gaps in Knowledge and Treatment.Orthopaedic journal of sports medicine · 2025Review
- Callus organoids reveal distinct cartilage to bone transition mechanisms across donors and a role for biological sex.Bone research · 2025Article
- Novel Method for Routine Ultrasound-Guided Serum Collection for Biomarker Analysis Around the Knee Joint.F1000Research · 2025Article
- An osteoarthritis pathophysiological continuum revealed by molecular biomarkers.Science advances · 2024Article
- Three decades of advancements in osteoarthritis research: insights from transcriptomic, proteomic, and metabolomic studies.Osteoarthritis and cartilage · 2024Review
- Serum proteomic panel validated for prediction of knee osteoarthritis progression.Osteoarthritis and cartilage open · 2024Article
- Serum proteomic biomarkers diagnostic of knee osteoarthritis.Osteoarthritis and cartilage · 2024Article
- Chronic Pain and Bone-Related Pathologies: A Narrative Review.Journal of pain research · 2024Review
- Markers of Tissue Deterioration and Pain on Earth and in Space.Journal of pain research · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
We aimed to identify markers in blood (serum) to predict clinically relevant knee osteoarthritis (OA) progression defined as the combination of both joint structure and pain worsening over 48 months. A set of 15 serum proteomic markers corresponding to 13 total proteins reached an area under the receiver operating characteristic curve (AUC) of 73% for distinguishing progressors from nonprogressors in a cohort of 596 individuals with knee OA. Prediction based on these blood markers was far better than traditional prediction based on baseline structural OA and pain severity (59%) or the current "best-in-class" biomarker for predicting OA progression, urinary carboxyl-terminal cross-linked telopeptide of type II collagen (58%). The generalizability of the marker set was confirmed in a second cohort of 86 individuals that yielded an AUC of 70% for distinguishing joint structural progressors. Blood is a readily accessible biospecimen whose analysis for these biomarkers could facilitate identification of individuals for clinical trial enrollment and those most in need of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.